793 abstracts found.



Results filter

Role of Protein Phosphatase 4 in Chronic Myeloid Leukaemia

Year:

Session type:

Sundus Al-Khazraji1,Mirna Mourtada-Maarabouni1

1Keele University, Staffordshire, UK


Initial experience of an algorithm-based programme for the community follow-up of patients with stable prostate cancer

Year:

Session type:

Jessica Little1,Philip Goodall1,Eleanor Robinson1,Ian Trimble2,Owen Cole3,Thomas Walton1,

Department of Urology, Nottingham University Hospitals NHS Trust, Nottingham, UK1,Nottingham City Clinical Commissioning Group, Nottingham, UK2,Royal Guernsey Hospital, Guernsey, UK3


Medicines and Consumables Wastage: Clinical Research Unit (CRU) Audit 2015

Year:

Session type:

Cyper Allan1,Katharine Williams1,Catharine Spalton1

1University of Sheffield, Sheffield, South Yorkshire, UK


Tumour-induced reprogramming of hepatic metabolism causes failure of anti-cancer immunotherapy

Year:

Session type:

Thomas Flint1,Tobias Janowitz1,2,Claire Connell1 (presenting),Ian Beh1,Edward Roberts5,Alice Denton3,Anthony Coll4,Duncan Jodrell1,Douglas Fearon6,7

1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK,2Department of Oncology, University of Cambridge, Cambridge, UK,3Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK,4University of Cambridge Metabolic Research Laboratories, Cambridge, UK,5Department of Pathology, University of California, San Francisco, CA, USA,6Cold Spring Harbor Laboratory, NY, USA,7Weill Cornell Medical College, New York, NY, USA


Sarah Cannon Research Institute UK (SCRI UK) and University College London – Advanced Diagnostics (UCL-AD) Genomics Review Board (GRB) Implementation and Experience

Year:

Session type:

Gabriel Mak1,Teresa Curiel1,Saeed Rafii1,Mark Voskoboynik1,Nataliya Rozumna-Martynyuk1,David Collin1,3,Phil Bennett2,Debbie Haynes1,Charles Swanton3,Hendrik-Tobias Arkenau1

1Sarah Cannon Research Insitute UK, London, UK,2University College London – Advanced Diagnostics, London, UK,3University College London Hospitals and Cancer Institute, London, UK


Lung Metastectomy and Colorectal Cancer: Patient Outcomes and Prognostic Factors

Year:

Session type:

Ciara O’Brien1,Rachel Broadbent1,Kandadai Rammohan2,Michael Braun1

1The Christie Hospital NHS Foundation Trust, Manchester, UK,2University Hospital of South Manchester NHS Foundation Trust, Manchester, UK


Increasing the frequency of physical activity very brief advice for cancer patients.  Development of an intervention using the Behaviour Change Wheel. 

Year:

Session type:

Justin Webb1,2,Jo Foster1,Edward Poulter1

1Macmillan Cancer Support, London, UK,2University of Hertfordshire, Hertfordshire, UK


Survival-predictive cell surface proteins in multiple myeloma: Mining publicly available gene expression data to identify novel biomarkers and targets for therapy

Year:

Session type:

Jason Sangha1,2

1Leeds Teaching Hospitals NHS Trust, Leeds, UK,2Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, UK


Increasing the frequency of physical activity very brief advice for cancer patients – a mixed methods feasibility study of a training intervention for nurses.

Year:

Session type:

Justin Webb1,2,Jen Hall3,Kirsten Hall4,Raheelah Ahmad2

1Macmillan Cancer Support, London, UK,2University of Hertfordshire, Hertfordshire, UK,3Brunel University, London, UK,4Bath University, Bath, UK


CD15/FUT4 overexpression on cancer cells decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.

Year:

Session type:

Guido Giordano1,Pietro Parcesepe2,Massimo Pancione3

1Medical Oncology Unit, Fatebenefratelli Hospital, Benevento, Italy,2Department of Pathology and Diagnostics, University of Verona, Verona, Italy,3Department of Sciences and Technologies, University of Sannio, Benevento, Italy


A novel highly invasive transitional phenotype during development of gefitinib resistance in oral squamous cell carcinoma is linked to activation of the PI3K/Akt pathway

Year:

Session type:

Julie Hamilton1,David Argyle2,Gura Bergvist2,Donald Yool2

1Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, UK,2Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Hospital for Small Animals, Easter Bush, Roslin, Midlothian, UK


standardisation of high throughput spheroid engineering using the labcyte echo acoustic dispenser

Year:

Session type:

michelle barnard2,adrienne flanagan2,susanne scheipl2,aurore lejeune1

1Labcyte, Sunnyvale, USA,2UCL Cancer Institute, London, UK


90 day mortality in radical radiotherapy – a retrospective population based study of 18,300 treatment episodes

Year:

Session type:

Katie Spencer1,2,Eva Morris2,Emma Dugdale1,Rebecca Birch2,Rob Turner1,David Sebag-Montefiore2,1,Geoff Hall1,2,Adrian Crellin1

1Leeds Cancer Centre, Leeds, UK,2University of Leeds, Leeds, UK


The Vacuolar ATPase Subunit E regulates cell death in human breast cancer cells

Year:

Session type:

Saja Mohammed1,Mirna Mourtada-Maarabouni1

1Keele University, Staffordshire, UK


An audit of Trabectedin for the treatment of incurable soft tissue sarcoma, five years of patient experience in the Northern Centre for Cancer Care (NCCC), Newcastle upon Tyne

Year:

Session type:

Jane Margetts1,Elizabeth Reay1,Radha Todd1,Mark Verrill1

1Northern Centre for Cancer Care, Newcastle upon Tyne, UK


Mutations in the transcriptional repressor REST predispose to Wilms tumour

Year:

Session type: , ,

Shazia Mahamdallie1,Sandra Hanks1,Kristen Karlin2,3,Anna Zachariou1,Elizabeth Perdeaux1,Elise Ruark1,Chad Shaw3,Alexander Renwick3,Emma Ramsay1,Shawn Yost1,Anna Elliot1,The Wilms Tumor Susceptibility Collaboration (WTSC)1,Michael Capra4,Thomas McLean5,Anthony Renwick1,Sheila Seal1,Charles Stiller6,Neil Sebire7,Thomas Westbrook2,3,Nazneen Rahman1,8

1Division of Genetics & Epidemiology, Institute of Cancer Research, London, UK,2Verna & Marrs McLean Dept. of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA,3Dept of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA,4Our Lady’s Children’s Hospital, Dublin, UK,5Wake Forest University School of Medicine, Winston-Salem, USA,6Public Health England, Oxford, UK,7Dept of Histopathology and Paediatric Laboratory Medicine, Great Ormond Street Hospital, London, UK,8Cancer Genetics Unit, Royal Marsden Hospital NHS Foundation Trust, London, UK


Modifying the cut and thrust of cancer cells – the influence of the oncogene LYRIC/AEG-1 on gene splicing

Year:

Session type:

Hayley Luxton1,Nicola Brindle1,Ian Mills1,2,David Neal1,Hayley Whitaker1

1University of Cambridge, Cambridge, UK,2University of Oslo, Oslo, Norway


Incorporating epistasis interaction of genetic susceptibility Single Nucleotide Polymorphisms in a lung cancer risk prediction model

Year:

Session type:

Michael W. Marcus1,Olaide Y. Raji1,Stephen W. Duffy2,Robert P. Young3,Raewyn J. Hopkins3,John K. field1

1Roy Castle Lung Cancer Research Programme, the University of Liverpool Cancer Research Centre, Institute of Translational Medicine, the University of Liverpool. Liverpool L3 9TA, UK, Liverpool, UK,2Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, London, UK,3School of Biological Sciences; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, Auckland, New Zealand


A prospective study of anal cancer screening amongst three high risk groups; Final results of the ANALOGY study.

Year:

Session type:

Alice Schofield1,Laura Sadler1,Linsey Nelson1,Julie Burnett1,Sheila Russell2,Matthew Gittins3,Mina Desai4,Alexandra Sargent5,Raymond McMahon6,Ashish Suckthankar7,Stephen Higgins8,James Hill9,Emma Crosbie1,Julietta Patnick10,Henry Kitchener1

1Institute of Cancer Sciences, University of Manchester, Manchester, UK,2Renal Transplant Unit, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK,3Institute of Population Health, University of Manchester, Manchester, UK,4Manchester Cytology Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK,5Clinical Virology, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK,6Histopathology Department, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK,7Manchester Centre for Sexual Health, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK,8Department for Sexual Health and HIV, North Manchester General Hospital, Pennine Acute Hospital NHS Trust, Manchester, UK,9General Surgery, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK,10Public Health England, Sheffield, UK


Synthetic Tumor Networks for Translational Studies

Year:

Session type:

Gareth Bolitho1,Ashley Smith2,Charles Garson2,Balabhaskar Prabhakarpandian2,Kapil Pant2

1Stratech Scientific Ltd, Newmarket, UK,2Synvivo, AL, USA


Can WBRT be omitted in NSCLC patients with brain metastases not suitable for stereotactic radiosurgery or surgical resection? Results from the UK Medical Research Council QUARTZ randomised clinical trial.

Year:

Session type: , ,

Paula Mulvenna1,Matthew Nankivell2,Rachael Barton3,Corinne Faivre-Finn4,Paula Wilson5,Barbara Moore6,Elaine McColl7,Iona Brisbane8,Dave Ardron2,Benjamin Sydes2,Cheryl Pugh2,Tanya Holt9,Neil Bayman4,Sally Morgan10,Caroline Lee11,Kathryn Waite12,Richard Stephens2,Max Parmar2,Ruth Langley2

1Northern Centre for Cancer Care, Newcastle upon Tyne, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Castle Hill Hospital, East Yorkshire, UK,4The Christie, Manchester, UK,5Bristol Haematology & Oncology Centre, Bristol, UK,6University Hospital Llandough, South Glamorgan, UK,7Royal Victoria Infirmary, Newcastle upon Tyne, UK,8Beatson West of Scotland Cancer Centre, Glasgow, UK,9Mater Hospital, Brisbane, Queensland, Australia,10Nottingham University Hospitals, Nottingham, UK,11Weston Park Hospital, Sheffield, UK,12Queen Elizabeth Hospital, King’s Lynn, UK


microRNA-449a impedes the growth and invasion of brain tumour initiating cells

Year:

Session type:

Kastytis Sidlauskas1,Ningning Li1,Ying Zhang1,Sebastian Brandner1

1University College London, London, UK


Stimulated DW-MRI for radiotherapy planning: improving radiotherapy induced xerostomia in head and neck cancer patients

Year:

Session type:

Jonathan Wyatt1,Rachel Pearson2,Andrew Blamire2,Charles Kelly1,Jill McKenna1,Jim Snell1,Hazel McCallum1

1Northern Centre for Cancer Care, Newcastle upon Tyne, UK,2Newcastle University, Newcastle upon Tyne, UK


Targeting arginine auxotrophy in colorectal cancer

Year:

Session type:

Constantinos Alexandrou1,Saif Sattar1,Jennifer Higgins1,Hong Cai1,Mafalda Pires-Damaso1,Ankur Karmokar1,Lynne Howells1,Andreas Gesher1,Catherine Andreadi1,Karen Brown1,Alessandro Rufini1

1University of Leicester, Leicester, UK


Genome-wide DNA methylation and gene expression profiling of cancer-associated myofibroblasts (CAM) identifies cancer-induced DNA methylation changes that may regulate CAM-specific gene expression

Year:

Session type:

Hanna Najgebauer1,Triantafillos Liloglou2,Andrea Varro1,Christopher M Sanderson1

1Department of Cellular and Molecular Physiology, University of Liverpool, Liverpool, UK,2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK


Frameworks for understanding the cancer population

Year:

Session type:

Hannah McConnell1,Rachel White1,Jane Maher1,2

1Macmillan Cancer Support, London, UK,2Mount Vernon Cancer Centre, London, UK


Defining stromal characteristics which can predict neoadjuvant chemotherapy response in breast cancer

Year:

Session type:

Celine Pourreyron1,Patsy Whelehan1,Philip Coates1,Andrew South2,Sarah Vinnicombe1,Alastair Thompson3,Andrew Evans1,Frances Fuller-Pace1

1University of Dundee, Dundee, UK,2Thomas Jefferson University, Philadelphia, USA,3The University of Texas MD Anderson Cancer Center, Houston, USA


PTEN regulates cdc42-dependent morphogenesis through ?-arrestin1/ARHGAP21 signalling.

Year:

Session type:

Arman Javadi1,Ravi Deevi1,Charles Campbell1

1Centre for Cancer Research and Cell Biology, Belfast, UK


Developing a device to immobilize the breast during radiotherapy: A co-design approach with patients and health care professionals

Year:

Session type:

Heidi Probst1,Heath Reed1,Keeley Rosbottom1,Andrew Stanton1,Helen Crank1,Christopher Bragg2,Karen Collins1

1Sheffield Hallam University, Sheffield, UK,2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK


A retrospective observational study of length of stay in hospital after colorectal cancer surgery in England (1998-2010)

Year:

Session type:

Ariadni Aravani1,Elizabeth Samy2,James Thomas2,Phil Quirke1,Eva Morris1,Paul Finan1

1University of Leeds, Leeds, UK,2Public Health England, Leeds, UK


Molecular interactions between PAK4 and EGFR in ovarian carcinogenesis

Year:

Session type:

Ivy, Tsz-Lo Wong1,Oscar, Gee-Wan Wong1,Annie, Nga-Yin Cheung1

1Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong


Modelling the tumour microenvironment to identify novel loss of function mutations in breast cancer progression

Year:

Session type:

Barrie Peck1,Sarah Maguire1,Eamonn Morrison1,Patty Wai1,Rachael Natrajan0

1Institute of Cancer Research, London, UK


Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis

Year:

Session type:

Sebastian R. Nielsen1,Valeria Quaranta1,Andrea Linford1,Perpetua Emeagi1,Carolyn Rainer1,Almudena Santos1,Sakei Takao2,Keiko Takao2,Yong-Sam Kim3,4,Danielle Engel5,Fiona Campbell1,Daniel Palmer1,Jeong Heon Ko3,4,David Tuveson5,6,Emilio Hirsch7,Ainhoa Mielgo1,Michael C. Schmid1

1Department of Molecular and Clinical Cancer Medicine. University of Liverpool, Liverpool, Merseyside, UK,2Department of Physiology, University of Liverpool, Liverpool, Merseyside, UK,3Aging Intervention Research Center, KRIBB, Yuseong-gu, Deajeon 305-806, Democratic People’s Republic of Korea,4Korea University of Science and Technology, Yuseong-gu, Daejeon 305-350, Democratic People’s Republic of Korea,5Lustgarten Pancreatic Cancer Research Laboratory, Cold Spring Harbour Laboratory, Cold Spring Harbor, NY 11724, USA,6Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA,7Department of Molecular Biotechnology and Health Sciences, Center for Molecular Biotechnology, University of Torino, 10126 Turin, Italy


The Role of the Clinical Trials Set Up Specialist: From Protocol to Patient Trial Initiation within the Oncology Haematology Clinical Trials Team (OHCT)

Year:

Session type:

Sheela Medahunsi1,Nicholas Gomm1

1Guys and St Thomas’ NHS Foundation Trust, London, UK


Three cancer groups to explain the different complexity, intensity and longevity of broad clinical needs

Year:

Session type:

Rachel White1,Hannah McConnell1,Jane Maher1,2

1Macmillan Cancer Support, London, UK,2Mount Vernon Cancer Centre, Middlesex, UK


Aspirin inhibits mTOR signalling, protein synthesis and translation in colorectal cancer

Year:

Session type:

Asta Valanciute1,Karen Dunbar1,Malcolm Dunlop1,Farhat Din1

1Institute of Genetics and Molecular Medicine, Edinburgh, UK


Computational tools for studying chromosome dynamics and instability

Year:

Session type:

Elina Vladimirou1,Andrew McAinsh1

1University of Warwick, Coventry, UK


Living on benefits: How cancer screening is portrayed in the national press

Year:

Session type:

Jack Bedeman1,Susanne Meisel1,Nora Pashayan1

1University College London, London, UK


5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer [CRUK/06/016]: report from the CHHiP Trial Management Group

Year:

Session type: , ,

Emma Hall1,Isabel Syndikus2,Helen Mossop1,John Staffurth3,Christopher Scrase4,Miguel Panades5,Julian Money-Kyrle6,John Logue7,Vincent Khoo8,John Graham9,David Bloomfield10,Alison Birtle11,Jean Tremlett10,Olivia Naismith8,Helen Mayles2,Shama Hassan1,Clare Cruickshank1,Clare Griffin1,David Dearnaley1,8

1The Institute of Cancer Research, London, UK,2Clatterbridge Cancer Centre, Wirral, UK,3Velindre Cancer Centre, Cardiff, UK,4Ipswich Hospital, Ipswich, UK,5Lincoln County Hospital, Lincoln, UK,6Royal Surrey County Hospital, Guildford, UK,7Christie Hospital, Manchester, UK,8Royal Marsden NHS Trust, London, UK,9Musgrove Park Hospital, Taunton, UK,10Royal Sussex County Hospital, Brighton, UK,11Royal Preston Hospital, Preston, UK


The impact of primary colorectal cancer treatment on physical symptoms and functioning in the first two years and self-efficacy: results from the ColoREctal Wellbeing (CREW) cohort study

Year:

Session type:

Claire Foster1,Joanne Haviland1,Jane Winter1,2,Chloe Grimmett1,Kim Chivers Seymour3,Lynn Calman1,Jessica Corner3,Amy Din1,Deborah Fenlon3,Christine M May1,Peter W Smith4,Alison Richardson2

1Macmillan Survivorship Research Group, Faculty of Health Sciences, University of Southampton, Southampton, UK,2University Hospital Southampton NHS Foundation Trust, Southampton, UK,3Faculty of Health Sciences, University of Southampton, Southampton, UK,4Southampton Statistical Sciences Research Institude, University of Southampton, Southampton, UK


REPORT-UK (Real-time Electronic Patient Outcome ReporTing of adverse events in UK cancer trials) – preliminary findings of the feasibility pilot study

Year:

Session type:

Fiona Kennedy1,Beverly Clayton1,Kate Absolom1,Elaine O’Connell Francischetto2,Louise Flintoff3,Katie Gordon1,Will Crocombe1,Vicky Hiley1,Jane Blazeby2,3,Julia Brown1,Galina Velikova1,4

1University of Leeds, Leeds, UK,2University of Bristol, Bristol, UK,3University Hospitals Bristol NHS Foundation Trust, Bristol, UK,4Leeds Teaching Hospitals NHS Trust, Leeds, UK


Research capacity and attitudes in UK Cellular Pathology

Year:

Session type:

Bridget Wilkins1,2,Elliann Fairbairn3

1NCRI, London, UK,2Guy’s and St Thomas’ Hospital, London, UK,3CR-UK Experimental Cancer Medicine Centres Network, London, UK


The association of red and processed meat, and dietary fibre with colorectal cancer in UK Biobank

Year:

Session type:

Kathryn Bradbury1,Tim Key1

1University of Oxford, Oxford, UK


Combination of physical and chemical therapy with vascular disruption by acoustic doxorubicin-loaded nanodroplet vaporization.

Year:

Session type:

Yi Ju Ho1,Chih Kuang Yeh1

1National Tsing Hua University, Hsinchu, Taiwan


HTLV-1 Tax oncoprotein is considered a key factor in HTLV-1 pathogenicity. BRCA1 gene dysfunction can lead to breast cancer development. In contrast to the tumor suppressor nature of BRCA1, Tax is a potent oncoprotein. Therefore, we hypothesize that HTLV-1 Tax expression in breast epithelial cells can antagonize BRCA1 expression and functionality, thereby sensitizing these cells to malignant transformation by environmental carcinogens. Our objective was to provide molecular and cellular indications to validate this hypothesis. earlier findings that the milk of HTLV-1 infected women is rich in HTLV-1 infected lymphocytes that can transfer the virus into breast epithelial cells, the outcomes of this project may point that HTLV-1 can be a risk factor for the development of breast cancer, with a substantially higher risk to women who practice long-term breastfeeding. Our results showed that Tax strongly inhibited estrogen induced activation of BRCA-1 expression in breast cells by sequestering CBP/p300 co-activators. Trying to explore the CBP/p300 associated mechanism of Tax effect on BRCA1 expression, our results suggest that Tax does not prevent the binding of CBP/p300 to ER? but rather physically associates with the ER?-CBP/p300 to form a tertiary reporter.Tax associates with ER?-CBP/p300 complex through binding to CBP/p300 rather than to the ER? protein These results support the possibility of HTLV-1 involvement in breast cancer development. our results showed that in contrast to the inhibitory effect of Tax on E2-ER? induced BRCA1 expression, Tax strongly enhanced the E2-ER? induced expression of genes containing the estrogen responsive elements (ERE) in their promoters.

Year:

Session type:

Ammar Abou Kandil1,Mahmoud Huliehel1

1Ben-Gurion University of the Negev, Beer Sheva, Israel


Would a structured Research-Nurse led consultation improve patient adherence to investigational medicinal products (IMPs) in clinical research trials?

Year:

Session type:

Collette Pigden1,Claire Glendon1,Piranavan Sucindran1,Sharon Whelan1,Nicholas Gomm1

1Oncology and Haematology Clinical Trials (OHCT), Guys and St. Thomas’ NHS Foundation Trust, London, UK


Actions of dobutamine in 3D multicellular pancreatic cancer spheroid models

Year:

Session type:

Bailu Xie1,Emma Harvey1,Randall Mrsny1,Stephen Ward1,Makoto Furutani-Seiki1

1University of Bath, Bath, UK


A 3-D model to determine the spatial distribution of internalized radioisotopes into individual cancer cells

Year:

Session type:

Georgina Royle1,Nadia Falzone1,3,Radka Chakalova2,Katherine Vallis1,Sverre Myhra2

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford,, Oxford, UK,2Department of Materials, University of Oxford, Oxford, UK,3University of Technology,, Pretoria, South Africa


Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Year:

Session type: , ,

Richard Hubner1,Li-Tzong Chen2,3,Daniel D. Von Hoff4,5,Chung-Pin Li6,7,Andrea Wang-Gillam8,György Bodoky9,Andrew Dean10,Yan-Shen Shan2,3,Gayle Jameson5,11,Teresa Macarulla12,13,Kyung-Hun Lee14,Jean-Frédéric Blanc15,Chang-Fang Chiu16,Gilberto Schwartsmann17,Jens T. Siveke18,Fadi S. Braiteh19,Victor M. Moyo20,Bruce Belanger20,Eliel Bayever20,David Cunningham21

1The Christie NHS Foundation Trust, Manchester, UK,2National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan,3National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan,4HonorHealth, Scottsdale, AZ, USA,5TGen, Scottsdale, AZ, USA,6Taipei Veterans General Hospital, Taipei, Taiwan,7National Yang-Ming University, Taipei, Taiwan,8Washington University in St. Louis, St. Louis, MO, USA,9St László Teaching Hospital, Budapest, Hungary,10St John of God Hospital, Subiaco, Western Australia, Australia,11Scottsdale Healthcare, Scottsdale, AZ, USA,12Vall d’Hebron University Hospital, Barcelona, Spain,13Vall d’Hebron Institute of Oncology, Barcelona, Spain,14Seoul National University Hospital, Seoul, Republic of Korea,15Hôpital Saint-André, Bordeaux, France,16China Medical University Hospital, Taichung, Taiwan,17Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil,18Klinikum rechts der Isar der TU München, Munich, Germany,19Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA


NKG2D ligand a chemotherapeutic effector enhances apoptosis in breast cancer cell line

Year:

Session type:

Habeeb Bankole1,Mervin Meyer1,Ashley Pretorius1

1Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa